A recent study suggests that patients who stop using blockbuster slimming jabs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who stop conventional lifestyle regimens.
Published data in a major health publication shows that while obese individuals can lose a large proportion of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People buying these treatments need to be aware of the potential of rapid rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to original mass in about a year and a half.
Analyzing Approaches
The study, which examined dozens of trials involving thousands of patients, contrasted the results of these new drugs with older methods.
Researchers point out that people who shed pounds through diet and exercise usually see a slower weight regain—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Experts believe the mode of action of the injections accounts for the accelerated regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to hunger is no longer kept in check, making overeating much more probable."
A Lifelong Disease?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of relapse, the therapy is often long-term.
This view is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
User Experiences
People who have discontinued the medication describe a intense resurgence of hunger.
"It was like something that goes on and you're instantly extremely hungry," recalled an individual.
This difficulty is exacerbated if individuals have not established sustainable dietary or behavioural changes during therapy.
Significant Use
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is greater among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone fix and lasting health benefits relies on ongoing behavioural management.
